SLIDE 1
04/ 2008
- M. Obermeier
Medizinisches Labor Berg
4/ 2008
HIV-GRADE HBV-Tool M. Obermeier 04/ 2008 Medizinisches Labor Berg - - PowerPoint PPT Presentation
HIV-GRADE HBV-Tool M. Obermeier 04/ 2008 Medizinisches Labor Berg - - PowerPoint PPT Presentation
HIV-GRADE HBV-Tool M. Obermeier 04/ 2008 Medizinisches Labor Berg Daten- bank HIVdb HIVdb Core Module HIV-SEQ Basis: Stanford HIVdb HIV-ALG 4/ 2008 Analysis flowchart Sequence data Mutation list Alignment on Pan- Genotype Consensus
SLIDE 2
SLIDE 3
4/ 2008
Analysis flowchart
Sequence data Mutation list
Identification of available genes Alignment on Pan- Genotype Consensus Identification of mutations
Analysis of mutations based on the algorithm Detailled output Tabular output
Identification of genotype and re-alignment on genotype specific consensus-sequence
SLIDE 4
4/ 2008
Algorithm Specification Interface (ASI)
Rules based algorithms can be
described in xml-format HBV-ruleset can be described in a format that is compatible to other algorithms
SLIDE 5
4/ 2008
HBV drug resistance mutations
SLIDE 6
4/ 2008
Algorithm
RT-Inhibitors: Lamivudine Resistance Possible Resistance 204ISV 180M 173L 80VI Adefovir Resistance Possible Resistance 236T 233V A181STV
SLIDE 7
4/ 2008
Algorithmus
Entecavir Resistance Possible Resistance 204IV and 1 of (169T, 184AGILS, 202CGI, 250IV) 1 of (169T, 184AGILS, 202CGI, 250IV) 204IV and 1 of (173L, 180M)
Comment: 204VI => A mutation M204VI alone only slightly impairs the susceptibility to entecavir, however the dose of entecavir should be increased according to the manufacturers instructions
Tenofovir Resistance Possible Resistance 194T
SLIDE 8
4/ 2008
Algorithm
Telbivudine Resistance Possible Resistance 204ISV 180M
SLIDE 9
4/ 2008
Algorithm
HBs-antigen-escape
HBs-escape 1 of (137W, 141W, 144HA, 145R, 147S)
SLIDE 10
4/ 2008
Sequence input
SLIDE 11
4/ 2008
Output of sequence length and genotype
SLIDE 12
4/ 2008
Output of RT-Alignment
SLIDE 13
4/ 2008
Output of HBsAg alignment
SLIDE 14
4/ 2008
Analysis
SLIDE 15
4/ 2008
Analysis
SLIDE 16
4/ 2008
Analysis
SLIDE 17
4/ 2008
Patient BN
HIV Coinfected Therapy: TDF/ FTC, DRV, MVC HIV-VL < 50 Cop./ ml HBV-VL: 20.000.000 IU/ ml
SLIDE 18
4/ 2008
Patient BN
SLIDE 19
HIV-GRADE e.V.
Thomas Berg, Medizinisches Labor Dr. Berg, Berlin Patrick Braun, PZB Aachen Martin Däumer, Institut für Immunologie und Genetik Josef Eberle, Pettenkofer-Institut, München Robert Ehret, PZB Aachen Rolf Kaiser, Institut für Virologie, Köln Klaus Korn, NRZ für Retroviren, Erlangen Harm Müller, Fenner-Labor, Hamburg Martin Stürmer, Institut für Medizinische Virologie,
Frankfurt
Hauke Walter, NRZ für Retroviren, Erlangen Eva Wolf, MUC Research München